PATENT APPLICATION DOCKET NO.: 3462.1019-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Shuji Sakuma, Kiminori Atsumi and Keiichiro Kikukawa

Application No.:

10/587,966

Group:

1614

371(c) Date:

December 20, 2007

Examiner:

Not assigned

Confirmation No.:

6665

For:

ANTITUMOR AGENT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits; or before the mailing of a first office action after the filing of a Request for Continued Examination).
under 37 CFR 1.97(c) together with either: a Statement under 37 CFR 1.97(e), as checked below, or a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before any of a final action, notice of allowance, or an action that closes prosecution, whichever occurs first)
under 37 CFR 1.97(d) together with: a Statement under 37 CFR 1.97(e), as checked below, and a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action, notice of allowance, whichever occurs first, or if prosecution otherwise closes, but on or before payment of the issue fee)
under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application file. (Filed after payment of issue fee)

Statement	Under	37	CFR	1.	.97((e)

	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
Staten		der 37 CFR 1.704(d) (Patent Term Adjustment) to original applications (other than design) filed on or after May 29, 2000				
	Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.					
\boxtimes	Enclos	sed herewith is a Listing of References:				
		Copies of the cited references are enclosed except as indicated below.				
	\boxtimes	Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.				
		Copies of the cited references submitted with an Information Disclosure Statement in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed, are not required under 37 CFR 1.98(d)(1) and (2) and are thus not provided.				
		Pending non-published applications are not being provided, since the applications are available to the examiner.				
	The listed references were cited in the enclosed Search Report in counterpart foreign application [add application number], which is listed in the attached Listing of References.					
		concise explanation" requirement (non-English references) for reference(s) [] under R 1.98(a)(3) is satisfied by:				
		the explanation provided on the attached sheet.				
		the explanation provided in the Specification.				
		submission of the enclosed International Search Report.				
		submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.				
		the enclosed English language abstract.				

Metho	d of payment:
	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
	Please charge Deposit Account 08-0380 in the amount of \$[].
\boxtimes	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.
	Respectfully submitted,
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
	By Lauril E. Brook
	David E. Brook
	Registration No. 22,592
	Telephone: (978) 341-0036
	Facsimile: (978) 341-0136
	rd, MA 01742-9133 71409